E. R. Squibb Sons, Inc.

Bristol-Myers Squibb Compnay

Dinos P Santafianos

Eric M Gordon

Karnail S Atwal

Jeffrey O Saunders

Ravi K Varma

George C Rovnyak

Charles Z Ding

Kathleen M Poss

Sam T Chao

Syed Z Ahmed

Peggy J McCann

Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein X is alkyl, Y is a single bond, --CH.sub.2 --, --C(O)--, --O--, --S-- or --N(R.sup.8)-- where R.sup.8 is hydrogen, alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl or (cycloalkyl)alkyl, and R.sup.1 to R.sup.7 are as defined herein. These compounds have potassium channel activating activity and are useful, therefore for example, as cardiovascular agents.

4-arylamino-benzopyran and related compounds

Novel compounds useful, for example, for the treatment of ischemic conditions and arrhythmia are disclosed. The compounds have the formula ##STR1## wherein X is oxygen or sulfur and the R groups are as defined herein.

Aryl and heterocyclic substituted propenamide derivatives

Novel nitrogen-substituted mevinic acid derivatives which inhibit the activity of HMG-CoA reductase. Pharmaceutical compositions, and methods of use for the treatment or prevention of hypercholesterolemia, atherosclerosis, hyperlipoproteinaemia and hyperlipidemia are provided, as are novel methods for preparation and intermediate compounds.

Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA

##STR1## and pharmaceutically acceptable salts thereof possess activity as cell-selective HMG-CoA reductase inhibitors, thus making them useful as antihypercholesterolemic agents. In the above formula,

Sulfur-substituted mevinic acid derivatives

Growing community of inventors

Maplewood, NJ, United States of America

Dinos P Santafianos